TECH Stock Analysis: Bio-Techne | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.069m USD | 12M Return: 37.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 238M
EPS Trend: -19.8%
Qual. Beats: 0
Rev. Trend: 95.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bio-Techne Corporation (NASDAQ: TECH) is a Minneapolis-headquartered life sciences company that develops, manufactures, and sells reagents, instruments, and services used in research, diagnostics, and bioprocessing markets worldwide. Founded in 1976 as Techne Corporation and rebranded under its current name in November 2014, the company operates through two reporting segments: Protein Sciences and Diagnostics and Spatial Biology.
The Protein Sciences segment supplies biological reagents such as cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, along with proteomic analytical tools for protein analysis workflows. The Diagnostics and Spatial Biology segment provides diagnostic controls, calibrators, exosome-based molecular assays, in-situ hybridization assays for spatial tissue analysis, and reagents used in hematology, blood chemistry, and coagulation testing. Across both segments, the company sells into pharmaceutical, academic, and clinical laboratory customers.
Bio-Techne sits within the Life Sciences Tools & Services sub-industry, which supplies consumables and instruments to drug developers, research institutions, and clinical diagnostics labs. The companys reagent-heavy product mix supports a recurring-revenue model, as consumables such as antibodies and assay kits are typically purchased repeatedly by the same laboratory customers over time.
- Protein Sciences fuels growth on cell and gene therapy demand
- Spatial Biology and exosome diagnostics accelerate segment expansion
- Margins pressured by input costs and FX headwinds
| Net Income: 109.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.22 > 1.0 |
| NWC/Revenue: 44.17% < 20% (prev 37.89%; Δ 6.27% < -1%) |
| CFO/TA 0.12 > 3% & CFO 294.9m > Net Income 109.6m |
| Net Debt (170.8m) to EBITDA (258.0m): 0.66 < 3 |
| Current Ratio: 4.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (156.9m) vs 12m ago -1.26% < -2% |
| Gross Margin: 64.96% > 18% (prev 65.75%; Δ -0.80% > 0.5%) |
| Asset Turnover: 46.62% > 50% (prev 45.71%; Δ 0.90% > 0%) |
| Interest Coverage Ratio: 15.01 > 6 (EBIT TTM 157.6m / Interest Expense TTM 10.5m) |
| A: 0.21 (Total Current Assets 688.0m - Total Current Liabilities 153.3m) / Total Assets 2.55b |
| B: 0.45 (Retained Earnings 1.15b / Total Assets 2.55b) |
| C: 0.06 (EBIT TTM 157.6m / Avg Total Assets 2.60b) |
| D: 4.48 (Book Value of Equity 2.09b / Total Liabilities 465.3m) |
| Altman-Z'' = 7.95 = AAA |
| DSRI: 0.92 (Receivables 217.9m/237.1m, Revenue 1.21b/1.21b) |
| GMI: 1.01 (GM 65.75% / 64.96%) |
| AQI: 0.96 (AQ_t 0.61 / AQ_t-1 0.64) |
| SGI: 1.00 (Revenue 1.21b / 1.21b) |
| TATA: -0.07 (NI 109.6m - CFO 294.9m) / TA 2.55b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of July 02, 2026, the stock is trading at USD 71.00 with a total of 11,817,028 shares traded. Over the past week, the price has changed by +20.58%, over one month by +39.79%, over three months by +33.01% and over the past year by +37.15%.
Current recommended Stop Loss: 64.30 (which is 9.4% or 2.6 ATR below the current price).
Bio-Techne has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy TECH.
- StrongBuy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.8 | -7.4% |
P/E Trailing = 101.0
P/E Forward = 34.6021
P/S = 9.1421
P/B = 5.3083
P/EG = 0.9735
Revenue TTM = 1.21b USD
EBIT TTM = 157.6m USD
EBITDA TTM = 258.0m USD
Long Term Debt = 200.0m USD (from longTermDebt, last quarter)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 380.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 90.3m
Net Debt = 170.8m USD (calculated: Debt 380.6m - CCE 209.8m)
Enterprise Value = 11.2b USD (11.1b + Debt 380.6m - CCE 209.8m)
Interest Coverage Ratio = 15.01 (Ebit TTM 157.6m / Interest Expense TTM 10.5m)
EV/FCF = 41.69x (Enterprise Value 11.2b / FCF TTM 269.6m)
FCF Yield = 2.40% (FCF TTM 269.6m / Enterprise Value 11.2b)
FCF Margin = 22.27% (FCF TTM 269.6m / Revenue TTM 1.21b)
Net Margin = 9.05% (Net Income TTM 109.6m / Revenue TTM 1.21b)
Gross Margin = 64.96% ((Revenue TTM 1.21b - Cost of Revenue TTM 424.3m) / Revenue TTM)
Gross Margin QoQ = 66.88% (prev 64.65%)
Tobins Q-Ratio = 4.41 (Enterprise Value 11.2b / Total Assets 2.55b)
Interest Expense / Debt = 2.76% (Interest Expense 10.5m / Debt 380.6m)
Taxrate = 25.54% (37.6m / 147.1m)
NOPAT = 117.4m (EBIT 157.6m * (1 - 25.54%))
Current Ratio = 4.49 (Total Current Assets 688.0m / Total Current Liabilities 153.3m)
Debt / Equity = 0.18 (Debt 380.6m / totalStockholderEquity, last quarter 2.09b)
Debt / EBITDA = 0.66 (Net Debt 170.8m / EBITDA 258.0m)
Debt / FCF = 0.63 (Net Debt 170.8m / FCF TTM 269.6m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.22% (Net Income 109.6m / Total Assets 2.55b)
RoE = 5.49% (Net Income TTM 109.6m / Total Stockholder Equity 2.00b)
RoCE = 7.18% (EBIT 157.6m / Capital Employed (Equity 2.00b + L.T.Debt 200.0m))
RoIC = 4.99% (NOPAT 117.4m / Invested Capital 2.35b)
WACC = 9.76% (E(11.1b)/V(11.5b) * Re(10.03%) + D(380.6m)/V(11.5b) * Rd(2.76%) * (1-Tc(0.26)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -0.87%
[DCF] Terminal Value 73.53% ; FCFF base≈250.1m ; Y1≈286.7m ; Y5≈421.9m
[DCF] Fair Price = 31.36 (EV 5.08b - Net Debt 170.8m = Equity 4.91b / Shares 156.6m; r=9.76% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -19.80 | EPS CAGR: -0.78% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.98 | Revenue CAGR: 2.96% | SUE: -0.75 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.44 | Chg30d=+0.55% | Revisions=-56% | Analysts=8
[Analyst] Revisions Ratio: -56%